EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudie

Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis

Andrea Matteucci, Stefania Angela Di Fusco, Michela Bonanni, Gaetano Marino, Silvio Fedele, Federico Nardi, Furio Colivicchi

Journal of Clinical Lipidology · 2026-05 · 20 (5) · 1030-1039

DOI: 10.1016/j.jacl.2026.02.018 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Clinical Lipidology, 2026-05. Verfasst von Andrea Matteucci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy (Matteucci, Di Fusco, Marino, and Colivicchi); Department of …. Hauptthemen laut MEDLINE: Dicarboxylic Acids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fatty Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Many patients receiving maximally tolerated statins fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels, and multiple add-on nonstatin therapies are now available or in development, including obicetrapib and bempedoic acid. However, no direct comparison between these drugs is available. OBJECTIVE: We conducted a network meta-analysis of randomized, double-blind, placebo-controlled trials evaluating obicetrapib or bempedoic acid on top of statin therapy. METHODS: We conducted a network meta-analysis of randomized, double-blind, placebo-controlled trials evaluating obicetrapib or bempedoic acid on top of statin therapy. The primary outcome was the mean percentage change in LDL-C from baseline vs placebo. The secondary outcome was the mean percentage change in non-high-density lipoprotein cholesterol (non-HDL-C), treatment safety, including adverse events, serious adverse events, and cardiovascular composite endpoint. A random-effects model was used to synthesize evidence, test consistency, and generate treatment rankings. Heterogeneity and publication bias were also assessed. RESULTS: Six trials involving 6025 participants met the inclusion criteria. Obicetrapib resulted in a pooled LDL-C reduction of -33.17% (95% CI, -36.21 to -30.13) vs placebo, whereas bempedoic acid produced a reduction of -18.02% (95% CI, -18.83 to -17.21). The comparison of treatments showed an additional 15.15% in LDL-C reduction, favoring obicetrapib (95% CI, -18.30 to -12.00). There was no evidence of heterogeneity or inconsistency across the network (τ² = 0; I² = 0). Obicetrapib also showed a greater non-HDL-C reduction of -16.1% (95% CI, -19.1 to -13.1). Both drugs showed a comparable safety profile. Findings were consistent across multiple sensitivity analyses. No evidence of publication bias was detected. CONCLUSION: Among statin-treated patients requiring further LDL-C lowering, obicetrapib may represent an additional oral option to achieve the LDL-C target. Results should be interpreted in the context of currently available cardiovascular outcomes evidence, pending dedicated outcomes and long-term safety data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dicarboxylic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsFatty AcidsHumansCholesterol, LDLRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Bempedoic acidLDL-C levelsLow-density lipoprotein cholesterolNetwork meta-analysisObicetrapibRandomized controlled trialsStatins

Substanzen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLFatty Acids

Autor:innen und Institutionen

  • Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy (Matteucci, Di Fusco, Marino, and Colivicchi); Department of Experimental Medicine, Tor Vergata University, Rome, Italy (Matteucci…
  • Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy (Matteucci, Di Fusco, Marino, and Colivicchi).
  • Department of Experimental Medicine, Tor Vergata University, Rome, Italy (Matteucci and Bonanni).
  • Department of Interventional Cardiology, UOC Cardiologia, Sandro Pertini Hospital, Rome, Italy (Fedele).
  • Santo Spirito Hospital, Casale Monferrato, 15033 Alessandria, Italy (Nardi).

Zitieren

APA

Matteucci, A., Di Fusco, S. A., Bonanni, M., Marino, G., Fedele, S., Nardi, F., & Colivicchi, F. (2026). Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis. Journal of Clinical Lipidology, 20(5), 1030-1039. https://doi.org/10.1016/j.jacl.2026.02.018

Vancouver

Matteucci A, Di Fusco SA, Bonanni M, Marino G, Fedele S, Nardi F, et al. Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis. Journal of Clinical Lipidology. 2026;20(5):1030-1039. doi:10.1016/j.jacl.2026.02.018

BibTeX
@article{Matteucci2026,
  author = {Matteucci, Andrea and Di Fusco, Stefania Angela and Bonanni, Michela and Marino, Gaetano and Fedele, Silvio and Nardi, Federico and Colivicchi, Furio},
  title = {Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  volume = {20},
  number = {5},
  pages = {1030--1039},
  doi = {10.1016/j.jacl.2026.02.018}
}
Kostenlos starten →